KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Moderna (MRNA) Assets: 2017-2025

Historic Assets for Moderna (MRNA) over the last 7 years, with Sep 2025 value amounting to $12.1 billion.

  • Moderna's Assets fell 23.21% to $12.1 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $12.1 billion, marking a year-over-year decrease of 23.21%. This contributed to the annual value of $14.1 billion for FY2024, which is 23.25% down from last year.
  • Per Moderna's latest filing, its Assets stood at $12.1 billion for Q3 2025, which was up 1.04% from $12.0 billion recorded in Q2 2025.
  • In the past 5 years, Moderna's Assets registered a high of $27.6 billion during Q1 2022, and its lowest value of $12.0 billion during Q2 2025.
  • Moreover, its 3-year median value for Assets was $15.8 billion (2024), whereas its average is $16.6 billion.
  • Per our database at Business Quant, Moderna's Assets surged by 513.97% in 2021 and then plummeted by 30.66% in 2024.
  • Quarterly analysis of 5 years shows Moderna's Assets stood at $24.7 billion in 2021, then increased by 4.82% to $25.9 billion in 2022, then dropped by 28.74% to $18.4 billion in 2023, then fell by 23.25% to $14.1 billion in 2024, then declined by 23.21% to $12.1 billion in 2025.
  • Its last three reported values are $12.1 billion in Q3 2025, $12.0 billion for Q2 2025, and $12.7 billion during Q1 2025.